Insulin injection - AntriaBio

Drug Profile

Insulin injection - AntriaBio

Alternative Names: AB 101; InsuLAR

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PR Pharmaceuticals
  • Developer AntriaBio
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 18 Jul 2017 Phase-I clinical trials in Type-1 diabetes mellitus in USA (SC)
  • 01 Jul 2017 IND application with the US FDA for a phase I trial for Type-1 diabetes mellitus becomes effective
  • 05 Jun 2017 AntriaBio files an IND application with the US FDA for initiation of a phase I trial for Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top